KRAS and neoplasm: Arms 1 vs. 2:PFS: HR = 0.85; 95% CI, 0.72-0.99; P = .048There was significant interaction between arm 1 and KRAS mutation status of tumor response (P = .03) but not for PFS (P = .07) or OS (P = .44)PFS in wild-type KRAS tumors: HR = 0.68, 95% CI, 0.50-0.94Safety: AEs were more frequently reported in arm 1Skin reactions (Gr 3): 19.7 vs. 0.2% (P < .001)Infusion-related reactions: 2.5 vs. 0% (P < .001)Diarrhea: 15.7 vs. 10.5% (P = .008)